S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 6.36 CNY 0.47%
Market Cap: 4.2B CNY

Shanghai MicuRx Pharmaceutical Co Ltd
Investor Relations

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 179 full-time employees. The company went IPO on 2022-08-05. The firm's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The firm also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The firm operates its businesses primarily in the domestic market.

Show more
Loading
688373
Shanghai Composite
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Yuan Zhengyu Ph.D.
CEO & Chairman
No Bio Available
Mr. Zhiyue Li
Deputy GM, CFO, Board Secretary & Director
No Bio Available
Mr. Xinghai Wang
Deputy GM, Senior VP & Chief Technology Officer
No Bio Available
Ms. Hong Yuan
Deputy GM & Chief Clinical Officer
No Bio Available
Mr. Liu Jingian
Head of Corporate Chemistry
No Bio Available
Ms. Wang Wen
Head of Biological Department
No Bio Available
Mr. Dongming Zhao
Deputy GM & GM of Kerui Kaisi
No Bio Available
Mr. Liang Lu
Chairman of the Supervisory Board, Director of the Quality & Compliance Department
No Bio Available

Contacts

Address
SHANGHAI
Shanghai
Building 2, 101, 1-4F, Building 1, No. 53, Edison Road, China (Shanghai) Pilot Free Trade Zone
Contacts
+862150900550
www.micurxchina.com